Home  Clinical trials Products in Development AZD3355
|
|
A number of clinical trials with AZD3355 Ongoing studies are currently in progress.
More studies will be added in due course. Additional AZD3355 Ongoing study information is available on ClinicalTrials.gov. | Study Number | Study Phase | Start Date | Recruitment Status | | D9120C00011 | Phase II | 1-Nov-2006 | Completed | | A randomized, double-blind, placebo controlled, phase IIA study to assess the effect on GERD symptoms, PK, safety and tolerability of 4 weeks treatment with AZD3355 65 mg bid as add-on treatment to a PPI in patients with an incomplete response to PPI. | | D9120C00011 | Phase II | 1-Nov-2006 | Completed | | A randomized, double-blind, placebo controlled, phase IIA study to assess the effect on GERD symptoms, PK, safety and tolerability of 4 weeks treatment with AZD3355 65 mg bid as add-on treatment to a PPI in patients with an incomplete response to PPI. | | D9120C00016 | Phase I | 27 Mar 2008 | Completed | | An open, randomised, three period cross, single centre, phase 1 pharmacokinetic interaction study of the reflux inhibitor AZD3355 150 mg bid and esomeprazole 40 mg od after 7 days of treatment in healthy volunteers | | D9120C00020 | Non-interventional study | 19 Feb 2007 | Completed | | A double-blind, placebo controlled, randomized, two centre phase IIA pharmacodynamic cross-over study to assess the effect of AZD3355, 65 mg bid, on transient lower esophageal sphincter relaxations (TLESRs) in GERD patients with an incomplete response to PPI treatment | D9120C00027
| Phase II | 27 May 2008 | Active, not recruiting | | Validation of patient-reported outcomes measures for the assessment of GERD symptoms and their subsequent impact on patients with partial response to PPI treatment in a two part multi-center phase IIa study including a four week randomised, double-blind, placebo-controlled, parallel-group treatment peroid | | D9120C00030 | Phase I | 4 Sep 2008 | Recruiting | | A phase 1 single centre single-blind randomised placebo-controlled study to assess the safety, tolerability and pharmacokinetics of oral AZD3355 after administration of single ascending doses and multiple repeated doses in healthy male volunteers | | D9120C00031 | Phase I | 7 Apr 2008 | Active, not recruiting | | A double-blind, randomized, cross-over design, phase 1 pharmacodynamic study to investigate the effect of different formulations of AZD3355 for the development of paresthesiae after dosing in healthy subjects |
|
|
|
|